ArticleLa Radiologia medica2025
Myocardial extracellular volume fraction with spectral detector computed tomography for risk stratification in non-ischemic heart failure.
Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- CT-derived myocardial extracellular volume: current evidence, clinical utility, and the emerging role of photon-counting CT-a systematic review.European radiology experimental · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo validate the feasibility of using late iodine enhancement (LIE)-derived ECV on iodine density images using spectral detector computed tomography (SDCT; CT-ECV) and to assess the potential of CT-ECV for risk stratification among patients with non-ischemic heart failure (NIHF). MATERIALS AND
methodsForty-five subjects who underwent cardiac SDCT and CMR were included in the validation group to calculate and compare CT-ECV with CMR-ECV to validate CT-ECV feasibility. Another 117 subjects (82 patients with NIHF, 35 controls) who underwent SDCT were included in the experimental group to explore the potential of CT-ECV for risk stratification. ECV was measured via iodine density images and CMR T1 mapping in accordance with American Heart Association 16-segment models.
resultsIn the validation group, there was no significant difference between CT-ECV and CMR-ECV (P = 0.293), with an insignificant bias. In the experimental group, CT-ECV in patients with NIHF was significantly higher than in controls (P < 0.05). In 82 patients with NIHF, CT-ECV in HFrEF ( HF with reduced ejection fraction: LVEF ≤ 40%) patients was statistically higher than that of HFmEF (HF with mildly reduced ejection fraction: LVEF 41-49%) and HFpEF (HF with preserved ejection fraction: LVEF ≥ 50%) patients (P < 0.05) and a significant difference among patients with NIHF with varied New York Heart Association classes (all P < 0.05); In addition, Kaplan-Meier survival curves and Log-rank test demonstrated that NIHF patients with CT-ECV ≥ 31.29% had higher probability of MACE than NIHF patients with CT-ECV < 31.29% (P < 0.001).
conclusionLIE-derived CT-ECV on iodine density images using SDCT is a promising practical alternative to CMR-ECV, with the potential to assist with risk stratification among patients with NIHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.